This inventor holds 8 USPTO granted patents and 1 published patent application. Top assignee: Ortho-Mcneil Pharmaceutical Corp.. Active years: 2010-2012.
Company Filing History:
Years Active: 2010-2012
Title: Innovations in Immunotherapy by Yan Kong
Introduction
Yan Kong is a prominent inventor based in Belle Mead, NJ (US), known for his significant contributions to the field of immunotherapy. With a total of 8 patents, his work focuses on developing innovative treatments for autoimmune and allergic diseases. His research has the potential to transform therapeutic approaches in these areas.
Latest Patents
One of Yan Kong's latest patents involves ex-vivo priming for generating cytotoxic T lymphocytes (CTLs) specific for non-tumor antigens. This groundbreaking work demonstrates that CTLs specific for antigenic peptides derived from the IgE molecule can be generated in vitro. By stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells, these IgE-specific CTLs can lyse target cells loaded with IgE peptides in vitro and inhibit antigen-specific IgE responses in vivo. Furthermore, the adoptive transfer of these CTLs to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. This innovative approach provides a promising treatment for allergic asthma and other IgE-mediated allergic diseases.
Additionally, antigenic peptides identified from non-tumor self-antigens induce specific CTLs in vitro. The CTLs induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTLs specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTLs induced by antigenic peptides derived from IgE specifically inhibit IgE responses. The adoptive transfer of CD40L-specific CTLs to NOD mice at an early age can delay the development of diabetes in these mice. This research highlights the potential of CTLs specific for non-tumor self-antigens in regulating immune responses in vivo.
Career Highlights
Yan Kong is currently associated with Ortho-McNeil Pharmaceutical Corporation, where he continues to advance his research in immunotherapy. His work has garnered attention for its innovative approach to treating complex diseases.
Collaborations
Yan has collaborated with notable colleagues, including Per A Peterson and Wei-Xing Shi, who contribute to his research endeavors.
Conclusion
Yan Kong's innovative work in immunotherapy showcases the potential of CTLs in treating autoimmune and allergic diseases. His contributions are paving the way for new therapeutic strategies that could significantly improve patient